Leadership Team

Leadership Team

Tom Burke
CEO
An accomplished Pharmaceutical/Biopharmaceutical veteran with 30+ diverse years of management experience leading a global pharmaceutical organization across multiple disciplines, including corporate leadership, operations (manufacturing/supply chain), business development (M&A, licensing), portfolio management, project management, P&L, sales and marketing. Tom received his MBA in Marketing from University of St. Thomas in Minneapolis, MN and a BASc in Economics from University of MN.

Marnie Peterson, Pharm.D., Ph.D.,
Vice President of Drug and Clinical Development
Marnie started her career as an academic scientist and clinician. Through her 20 years of experience, her work has evolved into an inventor and developer of therapeutics. She holds expertise in experimental and clinical pharmacology and microbial pathogenesis, with a focus in the development of new therapeutics for infectious diseases. Before joining Hennepin Life Sciences, Dr. Peterson was tenured faculty at the University of Minnesota Department of Experimental and Clinical Pharmacology. At the University, she successfully established a research program and was granted over $9 million dollars from the NIH, DOD, and various foundations and industrial partners. She holds a significant patent portfolio for her discoveries, one of which served as the basis for the establishment of Hennepin Life Sciences. She earned a Ph.D. in Infection from the University of Birmingham, Medical School, United Kingdom, and Pharm.D. and B.S. degrees from the University of Minnesota. 
William Houghton, MD
Medical Affairs
Chief Medical Officer at Anesiva, Eleos, Orphan Medical, clinical lead at Alexa Pharmaceuticals, Iotek Inc. and clinical leadership at Abbott Laboratories. . Education, list of companies he’s led….
Mark Robbins, Ph.D, J.D.
Regulatory Affairs
Dr. Robbins is a biopharmaceutical drug development professional with over 30 years of broad-based drug development and commercialization experience in both start-up and fully integrated pharmaceutical/biotechnology companies. His therapeutic area expertise includes CNS, cardiovascular, oncology, endocrine/metabolic, women’s heath, and diagnostics. Dr. Robbins is President of Kodiak Strategic Consultants. In that capacity, he also serves as the President of Tansna Therapeutics, a CNS drug development company, Chief Operating Officer of Bullet Biotechnology, an immunotherapy company and VP, Regulatory and Quality Assurance of QOL Medical. Prior to these roles, he served in senior management positions at Upsher-Smith Laboratories, Certus International, and Mallinckrodt and has had management responsibility overseeing all areas of Research and Development, Clinical Development, Regulatory Affairs, manufacturing, and supply chain functions. He has also implemented regulatory/clinical strategies leading to many successful NDA/BLA approvals. His business development expertise includes conducting pharmaceutical due diligence activities for in-licensing and out-licensing new pharmaceutical products as well as negotiation of licensing agreements. Dr. Robbins is a past Chair of the Food and Drug Law section of the Minnesota State Bar Association and taught Food and Drug law at various law schools. He received his B.S. degree in Biochemistry from UCLA, his Ph.D. in Pharmacology from the University of Minnesota Medical School, and his J.D. magna cum laude from Saint Louis University. 
Mike Killeen, C.P.A.
CFO
Mr. Killeen has been the Controller of Hennepin Life Sciences since January 2013. He has over twelve years of experience as an accounting professional, and over five years of financial management in the medical industry, most recently serving as financial reporting manager at Cardiovascular Systems, Inc. (Roseville, MN). Previously, from 2003 to 2007, Mike served as a supervisor and auditor in the public accounting industry at Grant Thornton, LLP (Minneapolis, MN) and completed a two year secondment overseas in Hong Kong, China serving American clients with international operations. From 2007 to 2009, he worked as a financial reporting analyst at Compellent Technologies in another technology-based growth environment following their initial public offering. Mr. Killeen is a licensed C.P.A (inactive) in the State of Minnesota and has a degree in accounting and management information systems from the Luther College.

Board Members

Bill Faulkner–Founder
Chairman
Senior-level experience in platform technology commercialization, private placements, and early stage company strategy, financing and operations across multiple industries. Currently has three (3) companies in his portfolio in biotech, energy, and related industry applications. Bill received his MBA in Finance and Economics from the University of Chicago Booth School of Business and a BS and BA in Physics and Economics from The University of Dallas. Bill was also a Lieutenant in the United States Navy and served as a Nuclear Engineer on the USS Enterprise. 
Douglas Wicks
Co-Founder
Dr. Wicks received his doctorate in Polymer Science and Engineering for the University of Massachusetts in Amherst. After receiving his degree Douglas work for Bayer Material Science in a variety of research roles eventually rising to VP for Coatings and Colarants Research at Bayer. Following his time at Bayer. Dr. Wicks was introduced to antimicrobial research while a professor at the University of Southern Mississippi There his research at the interface of polymer science and medicinal chemistry was focused on using failed antimicrobial pharmaceutical candidates as biocides. Dr. Wicks’s relationship with HLS co-founders William Faulkner and Prof. Patrick Schlievert, started in Minneapolis where he was employed in tventure capital backed industrial biotech. Dr. Wicks is currently the Director of Global R&D for Imerys Corp. 
Zeno W. Wicks III, Ph.D.
Boardmember
His areas of expertise are corn breeding, recurrent selection, experimental design and sustainable agriculture. He was author of multiple publications, lead on 6+ million research grants and elected to multiple national and regional scientific committees. He received multiple awards for teaching and research including recognition by the Kellogg Foundation and acceptance as a Fulbright Scholar in Ivory Coast where, speaking fluent French, he taught, did research and established numerous international exchange agreements. He is currently CEO of three successful startups in real estate development, impact investing in Africa and venture capital. Zeno earned his Ph.D. from North Dakota State University specializing in Plant Breeding. Zeno has recently retired from an extended and fruitful career as a corn researcher and educator at South Dakota State University. 
John Bullion
Advisor & Board Member
John was the Chief Executive Officer and Chairman of Orphan Medical, Inc., a NASDAQ listed specialty pharmaceutical company that developed and marketed eight (8) new drugs to treat rare diseases. He was responsible for the growth of this business from its spin-off until its sale 11 years later to Jazz Pharmaceuticals for nearly $150 million. He was also a co-founder of Chronimed, Inc., a specialty pharmaceutical distribution company, an early Board member of LifeTime Fitness and a Vice President and Partner of FBS Venture Capital Company. He has held Board, financial and operating positions in other small to large companies.​  He is currently the CEO and Chair of BoundaryMedical, Inc. whose systems allow medical providers to prove clinical outcomes and improve financial performance. John received his MBA from the University of Minnesota Carlson School of Management.